Compare BioNano Genomics Inc (BNGO) vs Unity Software Inc (U) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Unity Software Inc — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.66M), while Unity Software Inc trades at $43.83 (market cap $19.31B). The key difference: Unity Software Inc is far larger — about 1413.6× BioNano Genomics Inc's market cap, and Unity Software Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | U | |
|---|---|---|
Market Cap | $13.66M | $19.31B |
Sector | Health | Technology |
52-Week High | $4.92 | $49.47 |
52-Week Low | $1.06 | $17.13 |
Enterprise Value | $16.26M | $19.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
Unity Software (U) trades at $43.10, up 0.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $47.45. Recent Q2 2026 earnings beat expectations, with revenue growth of 24% year-over-year, driven by strong Vector advertising platform performance. The company reported positive operating cash flow of $422.96 million in 2025, though net income remains negative at -$402.77 million.
The outlook is mixed: strong revenue growth and analyst optimism support upside potential, but persistent net losses and high valuation ratios (P/S 9.33, EV/EBITDA 134.62) pose risks. Investors should weigh the company's path to GAAP profitability against competitive pressures in the software sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →
